Experience in genetic testing of hypertrophic cardiomyopathy using nanopore DNA sequencing
Open Access
- 22 November 2021
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (10) , 4673
Abstract
Aim. To investigate the application of the Oxford Nanopore Technologies’ third generation sequencing for the genetic testing of hypertrophic cardiomyopathy.Material and methods. The study involved 12 patients with hypertrophic cardiomyopathy aged 18 to 67 years (women, 9; men, 3). Using the PCR barcoding amplicons (SQK-LSK109) protocol, DNA libraries were created which contained long-range PCR fragments of the MYH7, MYBPC3, TNNT2, TNNI3 and TPM1 genes. The sequencing was performed using the MinION system by Oxford Nanopore Technologies (UK). Bioinformatic algorithms for data analysis included Guppy v.5.0.7, Nanopolish and Clairvoyante. The identified genetic variants were confirmed by Sanger sequencing.Results. Data on the complete sequence of the five major sarcomeric genes for hypertrophic cardiomyopathy were obtained. We found eight potentially disease-causing sequence variants in MYH7, MYBPC3 and TNNT2 genes by monomolecular sequencing. However, only three mutations p.Arg243Cys, p.Tyr609Asn, p.Arg870His in the MYH7 gene, and one mutation p.Lys985Asn in the MYBPC3 were confirmed by Sanger sequencing. Cascade screening of pathogenic variant p.Arg870His in the MYH7 gene was performed. We found one asymptomatic carrier.Conclusion. It appears that monomolecular sequencing technology is a feasible approach to identify mutations in patients with hypertrophic cardiomyopathy. Although improvement in accuracy of DNA sequencing, as well as optimization and simplification of bioinformatic algorithms for identification of the genetic variants are needed.Keywords
This publication has 24 references indexed in Scilit:
- Three decades of nanopore sequencingNature Biotechnology, 2016
- A complete bacterial genome assembled de novo using only nanopore sequencing dataNature Methods, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- New Perspectives on the Prevalence of Hypertrophic CardiomyopathyJACC, 2015
- Hypertrophic cardiomyopathy: from mutation to functional analysis of defective proteinCroatian Medical Journal, 2011
- A p.R870H mutation in the beta-cardiac myosin heavy chain 7 gene causes familial hypertrophic cardiomyopathy in several members of an Indian familyCanadian Journal of Cardiology, 2007
- Mutaciones en el gen de la cadena pesada de la betamiosina en pacientes con miocardiopatía hipertróficaRevista Espanola de Cardiologia, 2006
- Genotype‐phenotype correlation of R870H mutation in hypertrophic cardiomyopathyClinical Genetics, 2006
- Mutations in β-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C 1 1Edited by J. KarnJournal of Molecular Biology, 1999
- Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy.Proceedings of the National Academy of Sciences, 1995